Ro 28-1675

Research use only, not for human use.

A potent, allosteric activator of Glucokinase (GK) with SC1.5 of 0.24 uM.

A potent, allosteric activator of Glucokinase (GK) with SC1.5 of 0.24 uM; augments both hepatic glucose metabolism and glucose-induced insulin secretion from isolated rodent pancreatic islets; lowers blood glucose levels and increases hepatic glucose uptake in rodent models of type 2 diabetes mellitus. Diabetes Preclinical.

RO-28-1675 can reverse the inhibitory action of the human glucokinase regulatory protein (GKRP).

RO-28-1675 (50 mg/kg; p.o.) reduces blood glucose levels in wild-type C57BL/6J mice.RO-28-1675 exhibits high oral bioavailability (mice 92.8%) and Cmax (1140 μg/mL) following oral administration (10 mg/kg). Animal Model:10 weeks old male C57BL/6J mice Dosage:50 mg/kg Administration:Oral administration Result:Reduced blood glucose levels.Animal Model:C57BL/6J mice Dosage:10 mg/kg (Pharmacokinetic Analysis Administration:Oral administration Result:Oral bioavailability (92.8%), Cmax (1140 μg/mL), T max (3.3 h).

Ro 028-1675 | RO 0281675

Cytoskeleton/Cell Adhesion Molecules

Glucokinase

Glucokinase

Metabolic Disease

Diabetes

300353-13-3

378.5089

C18H22N2O3S2

>98% (HPLC)

10 mM in DMSO

O=C(NC1=NC=CS1)[C@@H](C2=CC=C(S(=O)(C)=O)C=C2)CC3CCCC3

Benzeneacetamide, α-(cyclopentylmethyl)-4-(methylsulfonyl)-N-2-thiazolyl-, (αR)-

(-20℃)

With Ice Pack

≥ 2 years